TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
TC BioPharm (NASDAQ: TCBP) has announced pricing for a $2.0 million registered direct offering. The biotechnology company, focused on developing allogeneic gamma-delta T cell therapies for cancer, will sell 2,000,000 American Depository Shares and Pre-Funded Warrants at $1 per share. Additionally, 2,000,000 cash exercise only Series G warrants with an exercise price of £0.78 will be offered to a single investor.
The company plans to use the net proceeds to support its upcoming clinical trial for relapse/refractory Acute Myeloid Leukemia, as well as for continuing operating expenses and working capital. A final prospectus supplement with additional offering details will be filed with the SEC.
TC BioPharm (NASDAQ: TCBP) ha annunciato il prezzo per un offerta diretta registrata di 2,0 milioni di dollari. L'azienda biotecnologica, focalizzata nello sviluppo di terapie con cellule T gamma-delta allogeniche per il cancro, venderà 2.000.000 di American Depository Shares e Warrant Pre-Finanziati a 1 dollaro per azione. Inoltre, verranno offerti a un singolo investitore 2.000.000 di warrant di Serie G con esercizio in contante, con un prezzo di esercizio di £0,78.
L'azienda prevede di utilizzare i proventi netti per supportare il suo prossimo trial clinico per la leucemia mieloide acuta in recidiva/refrattaria, oltre che per continuare a coprire le spese operative e il capitale circolante. Un supplemento del prospetto finale contenente ulteriori dettagli sull'offerta sarà presentato alla SEC.
TC BioPharm (NASDAQ: TCBP) ha anunciado el precio para una oferta directa registrada de 2,0 millones de dólares. La empresa biotecnológica, centrada en el desarrollo de terapias con células T gamma-delta alogénicas para el cáncer, venderá 2,000,000 de American Depository Shares y Warrants Pre-Financiados a 1 dólar por acción. Además, se ofrecerán 2,000,000 de warrants de la Serie G exclusivamente en efectivo a un único inversor, con un precio de ejercicio de £0,78.
La empresa planea utilizar los ingresos netos para respaldar su próximo ensayo clínico para leucemia mieloide aguda en recaída/refractaria, así como para continuar con los gastos operativos y el capital de trabajo. Se presentará un suplemento del prospecto final con más detalles sobre la oferta a la SEC.
TC BioPharm (NASDAQ: TCBP)는 200만 달러 규모의 등록 직접 제공 가격을 발표했습니다. 암을 치료하기 위해 알로젠 T 세포 요법을 개발하는 생명공학 회사인 이곳은 200만 개의 미국 예탁 주식 및 주식당 1달러에 선불 권리를 판매합니다. 또한, 한 투자자에게 ￡0.78의 행사 가격으로 200만 개의 현금 행사 전용 G 시리즈 워런트도 제공될 예정입니다.
회사는 순수익을 재발/내성 급성 골수성 백혈병을 위한 임상 시험 지원, 운영비 및 운전 자본의 지속적인 지원을 위해 사용할 계획입니다. 추가 제공 세부 사항을 포함한 최종 청약서 보충이 SEC에 제출될 예정입니다.
TC BioPharm (NASDAQ: TCBP) a annoncé le tarif pour une offre directe enregistrée de 2,0 millions de dollars. La société de biotechnologie, spécialisée dans le développement de thérapies par cellules T gamma-delta allogéniques pour le cancer, vendra 2.000.000 d'American Depository Shares et des Warrant Préfinancés à 1 dollar par action. De plus, 2.000.000 de warrants de série G uniquement disponibles en espèces, avec un prix d'exercice de £0,78, seront proposés à un seul investisseur.
La société prévoit d'utiliser les produits nets pour soutenir son prochain essai clinique pour la leucémie myéloïde aiguë en rechute/récalcitrante, ainsi que pour poursuivre les frais d'exploitation et le fonds de roulement. Un supplément de prospectus final avec des détails supplémentaires sur l'offre sera déposé auprès de la SEC.
TC BioPharm (NASDAQ: TCBP) hat die Preisgestaltung für ein registriertes Direktangebot in Höhe von 2,0 Millionen US-Dollar bekannt gegeben. Das biotechnologische Unternehmen, das sich auf die Entwicklung von allogenen gamma-delta T-Zelltherapien gegen Krebs konzentriert, wird 2.000.000 American Depository Shares und Vorab-Finanzierungs-Warrants zu einem Preis von 1 US-Dollar pro Aktie verkaufen. Darüber hinaus werden 2.000.000 Cash-Only-Serie-G-Warrants zu einem Ausübungspreis von £0,78 an einen einzigen Investor angeboten.
Das Unternehmen plant, die Nettomittel zur Unterstützung seiner kommenden klinischen Studie bei rezidivierenden/refraktären akuten myeloischen Leukämie sowie für laufende Betriebskosten und für Betriebskapital zu verwenden. Ein endgültiger Prospektzusatz mit weiteren Einzelheiten zur Wertpapieremission wird bei der SEC eingereicht.
- Secured $2.0 million in funding through a registered direct offering
- Proceeds will support upcoming clinical trial for relapse/refractory Acute Myeloid Leukemia
- Additional funding for continuing operating expenses and working capital
- Potential dilution of existing shareholders due to issuance of new shares
- Reliance on external funding may indicate financial constraints
Insights
TC BioPharm's
The inclusion of warrants in the deal adds complexity. If exercised, these could bring in additional capital but would further dilute existing shareholders. The cash-only exercise feature of the Series G warrants is noteworthy, as it ensures any future capital raised through these instruments will be in cash, not creating additional dilution through cashless exercises.
Investors should closely monitor the company's burn rate and clinical trial progress to assess whether this capital infusion will be sufficient to reach meaningful milestones.
The focus on relapse/refractory Acute Myeloid Leukemia (AML) for TC BioPharm's upcoming clinical trial is strategically significant. AML is a challenging cancer with high relapse rates and poor outcomes for refractory patients, representing a substantial unmet medical need. The company's allogeneic gamma-delta T cell therapy platform could potentially offer a novel approach to treating this difficult-to-manage condition.
However, investors should be aware that the clinical trial landscape for AML is highly competitive, with numerous companies exploring various immunotherapies and targeted treatments. TC BioPharm will need to demonstrate clear differentiation and superior efficacy to stand out in this crowded field. The
The gross proceeds to the Company from the offering are expected to be
The Company intends to use the net proceeds from this offering to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, and for continuing operating expenses and working capital. A final prospectus supplement containing additional information relating to the offering, will be filed with the SEC and will be available on the SEC's website at www.sec.gov.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the offering, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the Company's intent or ability to affect any budget savings or execute on any M&A or capital raising strategy. These statements are based on management's current assumptions and are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For other important factors that could cause actual results to differ materially from the forward-looking statements in this Current Report on Form 8-K, please see the risks and uncertainties identified under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other reports filed with the SEC, all of which is available on the Company's Investor Relations website at www.tcbiopharm.com and on the SEC website at www.sec.gov. All forward-looking statements reflect the Company's beliefs and assumptions only as of the date of this Current Report on Form 8-K. The Company undertakes no obligation to update forward-looking statements to reflect future events or circumstances.
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tc-biopharm-announces-pricing-of-2-0-registered-direct-offering-302221302.html
SOURCE TC BioPharm
FAQ
What is the size of TC BioPharm's (TCBP) recent registered direct offering?
How many shares and warrants are being offered by TC BioPharm (TCBP) in this offering?
What is the offering price per share for TC BioPharm's (TCBP) registered direct offering?
How does TC BioPharm (TCBP) plan to use the proceeds from this offering?
